197 related articles for article (PubMed ID: 15685233)
1. 17beta-Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer.
Gunnarsson C; Hellqvist E; Stål O
Br J Cancer; 2005 Feb; 92(3):547-52. PubMed ID: 15685233
[TBL] [Abstract][Full Text] [Related]
2. Enzymes as modulators in malignant transformation.
Vihko P; Herrala A; Härkönen P; Isomaa V; Kaija H; Kurkela R; Li Y; Patrikainen L; Pulkka A; Soronen P; Törn S
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):277-83. PubMed ID: 15860271
[TBL] [Abstract][Full Text] [Related]
3. Proliferative responses to altered 17beta-hydroxysteroid dehydrogenase (17HSD) type 2 expression in human breast cancer cells are dependent on endogenous expression of 17HSD type 1 and the oestradiol receptors.
Jansson A; Gunnarsson C; Stål O
Endocr Relat Cancer; 2006 Sep; 13(3):875-84. PubMed ID: 16954436
[TBL] [Abstract][Full Text] [Related]
4. 17Beta-hydroxysteroid dehydrogenase type 2: independent prognostic significance and evidence of estrogen protection in female patients with colon cancer.
Oduwole OO; Mäkinen MJ; Isomaa VV; Pulkka A; Jernvall P; Karttunen TJ; Vihko PT
J Steroid Biochem Mol Biol; 2003 Nov; 87(2-3):133-40. PubMed ID: 14672733
[TBL] [Abstract][Full Text] [Related]
5. New development in intracrinology of breast carcinoma.
Sasano H; Suzuki T; Nakata T; Moriya T
Breast Cancer; 2006; 13(2):129-36. PubMed ID: 16755106
[TBL] [Abstract][Full Text] [Related]
6. 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
Day JM; Foster PA; Tutill HJ; Parsons MF; Newman SP; Chander SK; Allan GM; Lawrence HR; Vicker N; Potter BV; Reed MJ; Purohit A
Int J Cancer; 2008 May; 122(9):1931-40. PubMed ID: 18183589
[TBL] [Abstract][Full Text] [Related]
7. 17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer.
Jansson A
J Steroid Biochem Mol Biol; 2009 Mar; 114(1-2):64-7. PubMed ID: 19167496
[TBL] [Abstract][Full Text] [Related]
8. 17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer.
Jansson AK; Gunnarsson C; Cohen M; Sivik T; Stål O
Cancer Res; 2006 Dec; 66(23):11471-7. PubMed ID: 17145895
[TBL] [Abstract][Full Text] [Related]
9. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
Jansson A; Delander L; Gunnarsson C; Fornander T; Skoog L; Nordenskjöld B; Stål O
Clin Cancer Res; 2009 May; 15(10):3610-6. PubMed ID: 19401349
[TBL] [Abstract][Full Text] [Related]
10. Human 17 beta-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression.
Miettinen MM; Mustonen MV; Poutanen MH; Isomaa VV; Vihko RK
Biochem J; 1996 Mar; 314 ( Pt 3)(Pt 3):839-45. PubMed ID: 8615778
[TBL] [Abstract][Full Text] [Related]
11. Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence.
Gunnarsson C; Olsson BM; Stål O;
Cancer Res; 2001 Dec; 61(23):8448-51. PubMed ID: 11731426
[TBL] [Abstract][Full Text] [Related]
12. 17Beta-hydroxysteroid dehydrogenases in normal human mammary epithelial cells and breast tissue.
Miettinen M; Mustonen M; Poutanen M; Isomaa V; Wickman M; Söderqvist G; Vihko R; Vihko P
Breast Cancer Res Treat; 1999 Sep; 57(2):175-82. PubMed ID: 10598044
[TBL] [Abstract][Full Text] [Related]
13. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
Pasqualini JR; Chetrite GS
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
[TBL] [Abstract][Full Text] [Related]
14. 17ss-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer.
Källström AC; Salme R; Rydén L; Nordenskjöld B; Jönsson PE; Stål O
Eur J Cancer; 2010 Mar; 46(5):892-900. PubMed ID: 20060711
[TBL] [Abstract][Full Text] [Related]
15. 17β-Hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer.
Sivik T; Gunnarsson C; Fornander T; Nordenskjöld B; Skoog L; Stål O; Jansson A
PLoS One; 2012; 7(7):e40568. PubMed ID: 22792371
[TBL] [Abstract][Full Text] [Related]
16. Estrogen metabolism as a regulator of estrogen action in the mammary gland.
Miettinen M; Isomaa V; Peltoketo H; Ghosh D; Vihko P
J Mammary Gland Biol Neoplasia; 2000 Jul; 5(3):259-70. PubMed ID: 14973388
[TBL] [Abstract][Full Text] [Related]
17. 17Beta-hydroxysteroid dehydrogenase type 1 in normal breast tissue during the menstrual cycle and hormonal contraception.
Söderqvist G; Poutanen M; Wickman M; von Schoultz B; Skoog L; Vihko R
J Clin Endocrinol Metab; 1998 Apr; 83(4):1190-3. PubMed ID: 9543139
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Brozic P; Lanisnik Risner T; Gobec S
Curr Med Chem; 2008; 15(2):137-50. PubMed ID: 18220769
[TBL] [Abstract][Full Text] [Related]
19. Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.
Hilborn E; Stål O; Jansson A
Oncotarget; 2017 May; 8(18):30552-30562. PubMed ID: 28430630
[TBL] [Abstract][Full Text] [Related]
20. Expression and regulation of 17 beta-hydroxysteroid dehydrogenase type 1.
Peltoketo H; Isomaa V; Poutanen M; Vihko R
J Endocrinol; 1996 Sep; 150 Suppl():S21-30. PubMed ID: 8943783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
